Analysts Set Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Target Price at $7.00

Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) have been assigned a consensus rating of “Moderate Buy” from the four analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation and three have issued a buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $6.6667.

ABOS has been the subject of several research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research note on Friday, January 9th. Wall Street Zen upgraded Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Sunday. Finally, BTIG Research reaffirmed a “buy” rating and issued a $8.00 price target on shares of Acumen Pharmaceuticals in a report on Thursday.

Insider Buying and Selling at Acumen Pharmaceuticals

In related news, CEO Daniel Joseph Oconnell sold 37,755 shares of the firm’s stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $1.99, for a total value of $75,132.45. Following the sale, the chief executive officer directly owned 619,982 shares of the company’s stock, valued at $1,233,764.18. This trade represents a 5.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders have sold 149,818 shares of company stock valued at $285,057 in the last quarter. 7.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Acumen Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. bought a new position in shares of Acumen Pharmaceuticals in the 3rd quarter worth $27,000. Independent Advisor Alliance purchased a new position in Acumen Pharmaceuticals in the fourth quarter worth $40,000. PFG Investments LLC increased its stake in Acumen Pharmaceuticals by 65.2% in the fourth quarter. PFG Investments LLC now owns 19,000 shares of the company’s stock valued at $40,000 after acquiring an additional 7,500 shares during the last quarter. Marshall Wace LLP bought a new position in Acumen Pharmaceuticals in the fourth quarter valued at $44,000. Finally, OMERS ADMINISTRATION Corp purchased a new stake in Acumen Pharmaceuticals during the fourth quarter valued at about $47,000. Hedge funds and other institutional investors own 71.01% of the company’s stock.

Trending Headlines about Acumen Pharmaceuticals

Here are the key news stories impacting Acumen Pharmaceuticals this week:

• Positive Sentiment: Acumen said it has $36M of funding to advance its EBD program and is targeting an ALTITUDE‑AD Phase II readout in late 2026 — this provides program funding visibility and a clear clinical milestone that could re‑rate shares if results are favorable. Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding
• Positive Sentiment: BTIG Research reaffirmed a “buy” rating and set an $8 price target, suggesting sizable upside from current levels and giving institutional validation to the company’s clinical strategy. BTIG buy rating and $8 price target coverage
• Positive Sentiment: Q4 results beat on the EPS line (reported $(0.41) vs. $(0.50) consensus), showing a smaller-than-expected loss and suggesting modest operating leverage as programs advance. Acumen Q4 EPS beat and earnings materials
• Neutral Sentiment: Company press release and earnings‑call highlights outlined strategic advances and program updates (full-year financials and business highlights), which provide context but no immediate new financing or partnership decisions. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Full-year 2025 financial report reiterates cash burn, program priorities and R&D focus — useful for modeling runway but not a catalyst by itself. Acumen reports financial results and business highlights
• Negative Sentiment: Acumen filed to sell 10.83 million shares of common stock on behalf of holders — a potential secondary that increases near‑term supply and dilution risk, which likely pressured the stock despite operational positives. Acumen files to sell 10.83M shares for holders

Acumen Pharmaceuticals Price Performance

ABOS stock opened at $2.26 on Friday. The firm has a 50 day moving average of $2.70 and a 200-day moving average of $2.17. The company has a current ratio of 4.07, a quick ratio of 4.07 and a debt-to-equity ratio of 0.32. Acumen Pharmaceuticals has a 12 month low of $0.86 and a 12 month high of $3.60. The firm has a market capitalization of $163.19 million, a P/E ratio of -1.12 and a beta of 0.20.

Acumen Pharmaceuticals (NASDAQ:ABOS) last posted its earnings results on Thursday, March 26th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.09. The firm had revenue of ($0.09) million for the quarter. As a group, sell-side analysts predict that Acumen Pharmaceuticals will post -1.56 earnings per share for the current fiscal year.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.